ALN-CFB

RNA / oligonucleotide

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Paroxysmal Nocturnal Hemoglobinuria
NCT07187401 · Regeneron Pharmaceuticals
2026-02-11 – 2031-07-15 · Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for Paroxysmal Nocturnal Hemoglobinuria: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
ALN-CFB: this drugPhase 1/2RNA / oligonucleotideComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
Eculizumab (Soliris)ApprovedMonoclonal antibodyComplement C5Weak signalFeatured results are safety only in this race
Iptacopan (Fabhalta)ApprovedSmall moleculeComplement Factor BPartial signal
NCT04558918: At 24 weeks, without transfusion: Hb increase of 2 g/dL or more in 51 of 60 on iptacopan vs 0 of 35 on anti-C5; Hb of 12 g/dL or more in 42 of 60 vs 0 of 35. Superiority shown on both primaries.
NCT04820530: Single arm, 24 weeks: estimated 92.2% (95% CI 82.5 to 100.0) of 40 complement-inhibitor-naive patients had a sustained Hb increase of 2 g/dL or more without transfusion. No comparator.
Pegcetacoplan (Empaveli)ApprovedPeptideComplement C3Partial signal
NCT03500549: Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP (Baseline and Week 16): Pegcetacoplan to Pegcetacoplan 2.37 Grams per deciliter (g/dL) (Standard Error 0.363) | Eculizumab to Pegcetacoplan -1.47 Grams per deciliter (g/dL) (Standard Error 0.666)
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
HRS-5965Phase 3UndisclosedComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
Pozelimab (Veopoz)Phase 3Monoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
FWY003
Phase 2(overall)
UndisclosedComplement Factor B
not yet graded(overall)
No reviewed efficacy summary in this indication
ZaltenibartPhase 2Monoclonal antibodyMASP-3Weak signal
NCT05972967: Interim (data cut-off 8 July 2024): primary endpoints were safety and tolerability; zaltenibart was well tolerated, treatment-related adverse events in 46.2% of patients (mostly mild to moderate), 1 discontinuation for a treatment-emergent serious adverse event. Hemoglobin rose from a mean baseline of 9.26 g/dL by 3.39 g/dL at day 29 and 3.27 g/dL at day 169 on add-on to ravulizumab (N=13), and by 3.85 g/dL at day 309 on monotherapy (N=6, P=0.003).

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow ALN-CFB to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
November 2029 (1)
Phase 1/2Paroxysmal Nocturnal HemoglobinuriaRecruiting
Est. primary completion 2029-11-29 · NCT07187401 · CT.gov ↗
What to watch

See the full readout calendar ↗